author-photo

Jennifer W. Oliver

Isis Pharmaceuticals

11

Papers

177

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

2019 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (54)
LBA19A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Wednesday 29 November 2016: Poster Sessions: Molecular targeted agents II: Poster (Board P116)437 - A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
437 - A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 4780: RXDX-107 exhibits multiple mechanisms of intracellular delivery and results in extensive drug-induced interstrand crosslinks in solid tumor preclinical models

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

2004 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (68)